Importance of collection tube during clinical studies of oseltamivir

被引：21

作者：

Lindegardh, Niklas

Davies, Geraint R.

Hien, Tran Tinh

Farrar, Jeremy

Singhasivanon, Pratap

Day, Nicholas P. J.

White, Nicholas J.

机构：

[1] Mahidol Univ, Fac Trop Med, Wellcome Trust Mahidol Univ Oxford Trop Med Res P, Bangkok 10400, Thailand

[2] Univ Oxford, Ctr Trop Med, Nuffield Dept Clin Med, Oxford OX1 2JD, England

[3] Univ Liverpool, Wellcome Trust Ctr Clin Trop Med, Liverpool L69 3BX, Merseyside, England

[4] Hosp Trop Dis, Ho Chi Minh City, Vietnam

来源：

ANTIMICROBIAL AGENTS AND CHEMOTHERAPY | 2007年 / 51卷 / 05期

基金：

英国惠康基金;

关键词：

D O I：

10.1128/AAC.01534-06

中图分类号：

Q93 [微生物学];

学科分类号：

071005 ; 100705 ;

摘要：

Ex vivo conversion of the anti-influenza drug oseltamivir to its active metabolite can be inhibited by the esterase inhibitor dichlorvos or by using commercial fluoride-oxalate tubes. Oseltamivir and its active metabolite remain intact in plasma samples during a proposed virus heat inactivation step: incubation at 60 degrees C for 45 min.

引用

页码：1835 / 1836

页数：2

共 12 条

[1]

[Anonymous], 2001, Guidance for Industry-bioanalytical method validation

[2] Brief report - Oseltamivir resistance during treatment of influenza A (H5N1) infection [J].

de Jong, MD ;

Thanh, TT ;

Khanh, TH ;

Hien, VM ;

Smith, GJD ;

Chau, NV ;

Cam, BV ;

Qui, PT ;

Ha, DQ ;

Guan, Y ;

Peiris, JSM ;

Hien, TT ;

Farrar, J .

NEW ENGLAND JOURNAL OF MEDICINE, 2005, 353 (25) :2667-2672

[3] Clinical pharmacokinetics of the prodrug oseltamivir and its active metabolite Ro 64-0802 [J].

He, G ;

Massarella, J ;

Ward, P .

CLINICAL PHARMACOKINETICS, 1999, 37 (06) :471-484

[4] Antivirals for influenza in healthy adults: systematic review [J].

Jefferson, T ;

Demicheli, V ;

Rivetti, D ;

Jones, M ;

Di Pietrantonj, C ;

Rivetti, A .

LANCET, 2006, 367 (9507) :303-313

[5] Rapid degradation of oseltamivir phosphate in clinical samples by plasma esterases [J].

Lindegardh, Niklas ;

Davies, Geraint R. ;

Hien, Tran Tinh ;

Farrar, Jeremy ;

Singhasivanon, Pratap ;

Day, Nicholas P. J. ;

White, Nicholas J. .

ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2006, 50 (09) :3197-3199

[6] DISINFECTION AND INACTIVATION OF THE HUMAN T-LYMPHOTROPIC VIRUS "TYPE-III/LYMPHADENOPATHY-ASSOCIATED VIRUS [J].

MARTIN, LS ;

MCDOUGAL, JS ;

LOSKOSKI, SL .

JOURNAL OF INFECTIOUS DISEASES, 1985, 152 (02) :400-403

[7] Vaccines and antiviral drugs in pandemic preparedness [J].

Monto, AS .

EMERGING INFECTIOUS DISEASES, 2006, 12 (01) :55-60

[8] Pharmacokinetics and dosage recommendations for an oseltamivir oral suspension for the treatment of influenza in children [J].

Osage C. ;

Barrett J. ;

Hill G. ;

Mann J. ;

Dorr A. ;

Dutkowski R. ;

Ward P. .

Paediatric Drugs, 2001, 3 (3) :229-236

[9]

SPIRE B, 1985, LANCET, V1, P188

[10] Heat inactivation of avian influenza and Newcastle disease viruses in egg products [J].

Swayne, DE ;

Beck, JR .

AVIAN PATHOLOGY, 2004, 33 (05) :512-518

← 1 2 →